![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2016
Anzahl der Publikationen: 2
2016
Hazel, Guy A. van; Heinemann, Volker; Sharma, Navesh K.; Findlay, Michael P. N.; Ricke, Jens; Peeters, Marc; Perez, David; Robinson, Bridget A.; Strickland, Andrew H.; Ferguson, Tom; Rodríguez, Javier; Kröning, Hendrik; Wolf, Ido; Ganju, Vinod; Walpole, Euan; Boucher, Eveline; Tichler, Thomas; Shacham-Shmueli, Einat; Powell, Alex; Eliadis, Paul; Isaacs, Richard; Price, David; Moeslein, Fred; Taieb, Julien; Bower, Geoff; Gebski, Val; Buskirk, Mark van; Cade, David N.; Thurston, Kenneth und Gibbs, Peter
(2016):
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
In: Journal of Clinical Oncology, Bd. 34, Nr. 15: S. 1723-1731
Gibbs, Peter; Heinemann, Volker; Sharma, Navesh K.; Findlay, Michael P. N.; Ricke, Jens; Peeters, Marc; Perez, David; Robinson, Bridget Anne; Strickland, Andrew; Ferguson, Tom; Rodriguez, Javier; Kroening, Hendrik; Wolf, Ido; Ganju, Vinod; Walpole, Euan Thomas; Boucher, Eveline; Tichler, Thomas E.; Gebski, Val; Buskirk, Mark van und Hazel, Guy A. van
(2016):
SIRFLOX: Differences in site of first progression between mFOLFOX6 +/- bevacizumab (bev) versus mFOLFOX6 +/- bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
In: Journal of Clinical Oncology, Bd. 34, Nr. 4